🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

EMD Serono Research & Development Institute clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, China and UK registers with EMD Serono Research & Development Institute as lead sponsor. Synced 26 Sep 2026
15Current trials
7Recruiting now
16Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

EMD Serono Research & Development Institute is the lead sponsor of 15 current clinical trials in our USA, China and UK registers. 7 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Avelumab, Bevacizumab and Enpatoran. The most-studied condition is Advanced Solid Tumor.

Company profile on this site (news, sites, medicines, approvals): Merck KGaA (DE) →

ClinicalTrials.gov trials by status

  • Recruiting747%
  • Not yet open17%
  • Active, closed747%

Trials by phase

  • Phase 1640%
  • Phase 3533%
  • Phase 2213%
  • Observational17%
  • Phase 1/217%
01

Clinical trials sponsored by EMD Serono Research & Development Institute

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412 · Metastatic Colorectal Cancer
Phase 3 Recruiting 2026-05 UK, USA, China
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2024-11 UK, USA
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891 · ClinicalTrials.gov ↗ · Cancer
Observational Recruiting 2022-10 UK, USA
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Drug: Enpatoran
Phase 3 Recruiting 2026-03 USA, China
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218 · ClinicalTrials.gov ↗ · Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Drug: Enpatoran
Phase 3 Recruiting 2026-04 USA, China
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
NCT07360314 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Recruiting 2026-02 USA
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
NCT07166601 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2025-10 USA
A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]
NCT07840287 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Phase 3 Not yet open 2026-10 USA
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132 · Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC)
Drug: M9140
Phase 1/2 Active, closed 2025-01 USA, China
Avelumab Program Rollover Study
NCT03815643 · ClinicalTrials.gov ↗ · Solid Tumors
Drug: Avelumab
Phase 3 Active, closed 2019-03 UK, USA
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 Active, closed 2022-08 UK, USA, China
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
NCT04170153 · ClinicalTrials.gov ↗ · Metastatic or Locally Advanced Unresectable Solid Tumors
Drug: Niraparib
Phase 1 Active, closed 2019-12 UK, USA, China
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992 · ClinicalTrials.gov ↗ · Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Phase 2 Active, closed 2016-09 USA, China
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
NCT06421935 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Active, closed 2024-08 USA
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030 · ClinicalTrials.gov ↗ · Colorectal Cancer
Phase 1 Active, closed 2022-08 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in EMD Serono Research & Development Institute trials

16 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in EMD Serono Research & Development Institute trials

17 conditions
Advanced Solid Tumor3Solid Tumors2Systemic Lupus Erythematosus (SLE)2Cutaneous Lupus Erythematosus (CLE)2Metastatic Colorectal Cancer1Locally Advanced or Metastatic Urothelial Carcinoma1Cancer1Metastatic or Locally Advanced Unresectable Solid Tumors1Gastric Cancer1Non-Small Cell Lung Cancer (NSCLC)1Pancreatic Cancer1Systematic Lupus Erythematosus1Cutaneous Lupus Erythematosus1Advanced Solid Tumors1Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification1Lung Adenocarcinoma Stage IIIB/IV1Colorectal Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA157
Clinical trials in China73
Clinical trials in UK63

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumor

SponsorTrials
BeOne Medicines11
Daiichi Sankyo7
TORL Biotherapeutics5
OncoC45
LaNova Medicines5
MediLink Therapeutics (Suzhou)4
Suzhou Zelgen Biopharmaceuticals4
BioNTech3
Hansoh BioMedical R&D Company3
Qilu Pharmaceutical3

Sponsors with the most current trials registered for this condition.

06

Questions about EMD Serono Research & Development Institute trials

How many clinical trials does EMD Serono Research & Development Institute sponsor?

EMD Serono Research & Development Institute is the lead sponsor of 15 current trials on ClinicalTrials.gov in our USA, China and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are EMD Serono Research & Development Institute trials recruiting?

Yes. 7 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is EMD Serono Research & Development Institute testing?

Its current trials name 16 drugs and biologicals as interventions. The most frequent are Avelumab (2), Bevacizumab (2), Enpatoran (2), M9140 (2) and Abiraterone (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.